Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Familial Hypercholesterolemia Clear all
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
AAV directed hLDLR gene therapy
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced May 21, 2026, 7:22 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Familial Hypercholesterolemia, Adherence, Medication
Interventions
Monetary incentives
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Hypercholesterolemia, Familial
Interventions
ISIS 301012 or Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Chicago, Illinois • Auburn, Maine • Scarborough, Maine + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
Bococizumab (PF-04950615;RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
22
States / cities
Los Angeles, California • Hartford, Connecticut • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
colesevelam HCl, placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
10 Years to 17 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
8
States / cities
Washington D.C., District of Columbia • St Louis, Missouri • New Hyde Park, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
CER-001
Drug
Lead sponsor
Cerenis Therapeutics, SA
Industry
Eligibility
12 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Hartford, Connecticut • North Massapequa, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
lerodalcibep, evolocumab
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
10 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Evanston, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions
mipomersen sodium
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Auburn, Maine • Biddeford, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
Interventions
Inclisiran Sodium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
141
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
14
States / cities
Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions
mipomersen, Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Charlotte, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced May 21, 2026, 7:22 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Familial Hypercholesterolemia
Interventions
Child(ren) receive an adult-onset result, Child(ren) received a pediatric-onset result, Control - Negative Result, Adolescents who received adult-onset result, Adolescents who received a pediatric-onset result, Adolescent controls - negative for familial variant
Genetic
Lead sponsor
Geisinger Clinic
Other
Eligibility
Not listed
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
Placebo, Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
2,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced May 21, 2026, 7:22 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Familial Hypercholesterolaemia
Interventions
Alert-based computerized decision support
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced May 21, 2026, 7:22 PM EDT
Terminated Phase 3 Interventional
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment
Drug
Lead sponsor
Takeda
Industry
Eligibility
8 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
10 Years to 17 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
The Bronx, New York • Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer, Brain Metastases
Interventions
ANG1005
Drug
Lead sponsor
Angiochem Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
19
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced May 21, 2026, 7:22 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Hypercholesterolemia, Familial
Interventions
Kinetics test
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced May 21, 2026, 7:22 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Implitapide
Drug
Lead sponsor
Medical Research Laboratories International
Industry
Eligibility
8 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 21, 2026, 7:22 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Hypercholesterolemia, Familial
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia, Coronary Artery Disease
Interventions
mipomersen sodium, placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
37
States / cities
La Jolla, California • Los Angeles, California • Mission Viejo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced May 21, 2026, 7:22 PM EDT